Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21
Regeneron's Q4 Double-Digit Top and Bottom-Line Growth Propelled By Higher Sales From Eylea And DupixentBenzinga • 02/05/21
Regeneron's stock rallies after profit rises well above expectations, while revenue matchesMarket Watch • 02/05/21
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating ResultsPRNewsWire • 02/05/21
Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week24/7 Wall Street • 01/31/21
Regeneron (REGN) COVID-19 Cocktail Effective Against New VariantsZacks Investment Research • 01/28/21
Could This Drug Be 100% Effective in Preventing Symptomatic COVID-19 Infections?The Motley Fool • 01/28/21
Regeneron says its COVID-19 antibody cocktail still works against new strains in lab testMarket Watch • 01/27/21
REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South AfricaPRNewsWire • 01/27/21